Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, D. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 25-41, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy


ORIGINAL ARTICLES

Beta-lactamase-mediated resistance and opportunities for its control

DM Livermore
Central Public Health Laboratory, London, UK. d.m.livermore@mds.amw.ac.uk

Clinical use of beta-lactams has selected for beta-lactamase-producing organisms. Numerous beta-lactamases are known, and sequencing allows them to be divided into four Classes, A to D, with Classes A and C being the most important. Pharmaceutical chemists have responded to the spread of beta-lactamase-producing organisms by developing stable agents and inhibitors. Stability in penicillins and cephalosporins is achieved by attaching a bulky substituent to the amino group of 6- aminopenicillanic acid or 7-aminocephalosporanic acid, or by replacing the hydrogen on carbon 6 (penicillins) or 7 (cephalosporins) with an alpha-methoxy group. In carbapenems, stability is achieved by incorporation of a simple trans-6-hydroxyethyl group. Beta-lactamase- inhibitory activity occurs in many beta-lactam classes but only clavams and penicillanic acid sulphones have been developed specifically as beta-lactamase inhibitors. These inhibit most Class A and some Class D enzymes but act poorly against Class B and C enzymes. Their success is affected by the amount of enzyme, the permeability of the bacterial cell wall, the partner beta-lactam and the pH. Piperacillin/tazobactam, which combines a good inhibitor of Class A enzymes with a broad- spectrum, easily-protected penicillin, has wide activity against common pathogens, the major exceptions being strains of Enterobacter, Serratia and Citrobacter freundii that produce large amounts of Class C enzymes, and Gram-positive cocci with modified penicillin-binding proteins. Beta- lactamase-stable beta-lactams and inhibitor combinations overcome many existing resistance mechanisms but are themselves selecting new resistances. Few new beta-lactams able to overcome these resistances are advanced in development and consequently the opportunities for control lie mostly in the more prudent use of compounds already available.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
S. See, E. K Scott, and M. W Levin
Penicillin-Induced Jarisch-Herxheimer Reaction
Ann. Pharmacother., December 1, 2005; 39(12): 2128 - 2130.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
T. G. Winstanley, H. K. Parsons, M. A. Horstkotte, I. Sobottka, and E. Sturenburg
Phenotypic detection of {beta}-lactamase-mediated resistance to oxyimino-cephalosporins in Enterobacteriaceae: evaluation of the Mastascan Elite Expert System
J. Antimicrob. Chemother., August 1, 2005; 56(2): 292 - 296.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
C.-I. Kang, H. Pai, S.-H. Kim, H.-B. Kim, E.-C. Kim, M.-d. Oh, and K.-W. Choe
Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type {beta}-lactamase
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1130 - 1133.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. W. Stone, Q. Zhang, R. Castillo, V. R. Doppalapudi, A. R. Bueno, J. Y. Lee, Q. Li, M. Sergeeva, G. Khambatta, and N. H. Georgopapadakou
Mechanism of Action of NB2001 and NB2030, Novel Antibacterial Agents Activated by {beta}-Lactamases
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 477 - 483.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
J. J.A. Huntley, W. Fast, S. J. Benkovic, P. E. Wright, and H. J. Dyson
Role of a solvent-exposed tryptophan in the recognition and binding of antibiotic substrates for a metallo-{beta}-lactamase
Protein Sci., July 1, 2003; 12(7): 1368 - 1375.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
M. Sanguinetti, B. Posteraro, T. Spanu, D. Ciccaglione, L. Romano, B. Fiori, G. Nicoletti, S. Zanetti, and G. Fadda
Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum {beta}-Lactamase Detection Method
J. Clin. Microbiol., April 1, 2003; 41(4): 1463 - 1468.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. H. Toney, G. G. Hammond, P. M. D. Fitzgerald, N. Sharma, J. M. Balkovec, G. P. Rouen, S. H. Olson, M. L. Hammond, M. L. Greenlee, and Y.-D. Gao
Succinic Acids as Potent Inhibitors of Plasmid-borne IMP-1 Metallo-beta -lactamase
J. Biol. Chem., August 17, 2001; 276(34): 31913 - 31918.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.